China is taking on the world’s 10 most expensive medicinesnews2026-03-05T15:00:17+00:00March 5th, 2026|Endpoints News|
Sanofi licenses Sino Biopharm’s transplant drug for $135M upfrontnews2026-03-04T12:05:54+00:00March 4th, 2026|Endpoints News|
UCB boards T cell engager train in $60M upfront deal with Antengenenews2026-03-04T08:51:51+00:00March 4th, 2026|Endpoints News|
China obesity biotech QL Biopharm gets $72M, including support from OrbiMednews2026-03-02T12:14:18+00:00March 2nd, 2026|Endpoints News|
US International Trade Commission to take a closer look at Chinese biotechnews2026-02-27T19:20:24+00:00February 27th, 2026|Endpoints News|
New biotech Slate Medicines raises $130M for migraine drug from Chinanews2026-02-24T12:30:21+00:00February 24th, 2026|Endpoints News|
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to marketnews2026-02-24T11:37:17+00:00February 24th, 2026|Endpoints News|
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic pushnews2026-02-24T08:30:05+00:00February 24th, 2026|Endpoints News|
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Actnews2026-02-23T19:56:05+00:00February 23rd, 2026|Endpoints News|
Frontier, Harbour do licensing deals with GSK, Solsticenews2026-02-23T15:03:25+00:00February 23rd, 2026|Endpoints News|
